Telomir Pharmaceuticals, Inc. (TELO)

NASDAQ: TELO · IEX Real-Time Price · USD
-0.07 (-0.84%)
Feb 28, 2024, 1:18 PM EST - Market open
Market Cap 262.79M
Revenue (ttm) n/a
Net Income (ttm) -4.23M
Shares Out 29.61M
EPS (ttm) -0.14
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 23,312
Open 8.74
Previous Close 8.95
Day's Range 8.60 - 9.00
52-Week Range 4.77 - 20.72
Beta n/a
Analysts n/a
Price Target n/a
Earnings Date n/a

About TELO

Telomir Pharmaceuticals is a pre-clinical-stage pharmaceutical company focused on the development and commercialization of TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic treatment for human stem cells. Based on our pre-clinical studies and if approved by the FDA and comparable foreign regulators, we believe that TELOMIR-1 may potentially serve as a metal enzyme inhibitor of essential metals such as zinc and copper. In particular, zinc is essential to the function of pro-inflammatory cytokines such a... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Feb 9, 2024
Employees 2
Stock Exchange NASDAQ
Ticker Symbol TELO
Full Company Profile

Financial Performance

Financial Statements


Telomir Pharmaceuticals Announces Closing of Initial Public Offering

BALTIMORE, Feb. 13, 2024 (GLOBE NEWSWIRE) -- Telomir Pharmaceuticals, Inc. (Nasdaq: TELO) (“Telomir” or the “Company”), a pre-clinical-stage pharmaceutical company focused on the development and comme...

14 days ago - GlobeNewsWire

Telomir Pharmaceuticals Announces Pricing of Initial Public Offering

Telomir Pharmaceuticals, Inc., a pre-clinical-stage pharmaceutical company focused on the development and...

19 days ago - GLOBE NEWSWIRE

Small molecule biotech Telomir Pharmaceuticals files for a $14 million IPO

Telomir Pharmaceuticals, a preclinical biotech developing an oral small molecule for age- and cancer-related conditions, filed on Tuesday with the SEC to raise up to $14 million in an initial public o...

3 months ago - Renaissance Capital

Telomir Pharmaceuticals IPO Registration Document (S-1)

Telomir Pharmaceuticals has filed to go public with an IPO on the NASDAQ.

3 months ago - SEC